Clinical Trial Update: LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

A Phase 2 trial (LUMINOS-101) evaluating Lerapolturev (PVSRIPO) in combination with pembrolizumab in recurrent glioblastoma has completed enrollment and posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Glioblastoma
• Supratentorial Glioblastoma

Drugs mentioned

• Lerapolturev (lerapolturev)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Istari Oncology, Inc. | Conditions: Glioblastoma, Recurrent Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2025-03-25